2024-12-31 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**1. Performance Summary and Comparison to S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading pharmaceutical company known for its diverse portfolio of prescription medicines, vaccines, and animal health products.

Over the analyzed period, MRK's cumulative return is 62.93%, significantly lagging behind the S&P 500's (VOO) cumulative return of 115.96%.  The difference is -53.0%, placing it at the 9.6th percentile of its historical range of performance relative to the S&P 500.  This indicates MRK has underperformed the market benchmark considerably.  The provided alpha consistently shows negative values (-0.1), further confirming underperformance relative to the market.  Beta values, however, are significantly greater than 1, indicating higher volatility than the market.


**2. Recent Price Movement:**

* **Closing Price:** $98.37
* **5-day Moving Average:** $99.35
* **20-day Moving Average:** $100.15
* **60-day Moving Average:** $102.01

The stock price is currently trading below its 5, 20, and 60-day moving averages, suggesting a downward trend.


**3. Technical Indicators and Expected Return:**

* **RSI:** 34.74 (Below 30 suggests oversold conditions)
* **PPO:** -0.0214 (Negative value indicates bearish momentum)
* **Recent Relative Strength Change (20-day):** +1.3 (Short-term upward movement, but still within a bearish trend given other indicators).
* **Expected Return (Long-term, 2+ years):** 54.4% (This exceeds the S&P 500's expected return, but the substantial negative alpha suggests caution.)

The current price of $98.37 doesn't indicate a dramatic recent price jump or drop based on the provided data; however, the RSI and PPO suggest bearish momentum. The expected return needs to be viewed within the context of the negative alpha.

**4. Recent Earnings Analysis:**

The provided earnings data shows some inconsistencies (duplicate entry for 2024-11-06).  Focusing solely on the unique entries and ignoring the duplicates:

* **Revenue:** Revenue has generally increased across reported quarters. 
* **EPS:** EPS fluctuates; there is no consistent upward or downward trend evident in the limited data available.  A deeper dive into the underlying reasons for EPS fluctuations (e.g., one-time events, seasonality) is needed.
* **Beats/Misses:** There is no information to compare the reported EPS against any expectations.

**5. Financial Information Analysis:**

**Revenue and Profitability:**  Revenue shows consistent growth, though the rate of growth fluctuates.  Profit margins are generally high but show some minor variability.


**Capital and Profitability:** Equity shows growth generally, although it declined slightly from Q2 to Q3 2024. ROE is highly variable, including a negative value in Q4 2023. This suggests significant volatility in profitability and potential underlying factors warranting further investigation.


**6. News and Recent Issues:**

No recent news or analyst opinions are provided.  More information is needed to assess current market outlook and expert viewpoints.


**7. Overall Analysis:**

Merck & Co Inc (MRK) shows strong revenue growth, generally high profit margins and significant equity.  However, the stock is currently underperforming the S&P 500 significantly, based on the given data. The price is below its moving averages, suggesting a bearish trend.  Technical indicators (RSI and PPO) support this.  Earnings data shows fluctuation in EPS without a clear trend.  The high, and volatile ROE, along with a negative alpha, indicates caution is warranted.  The forecast of a 54.4% long-term outperformance of the S&P 500 should be viewed skeptically in light of the consistent negative alpha. Further analysis, including news, analyst ratings, and a comparison to expectations, is needed to fully assess the investment potential of MRK. More complete and consistent data would aid in a more thorough evaluation.


**8. Disclaimer:** This report is based solely on the limited data provided. It is not financial advice.  Conduct thorough research and consult with a financial advisor before making any investment decisions.
